Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz 400mg vs 600mg in Treatment-naive HIV Patients
NCT04463784Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of efavirenz in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Change from Baseline Virological measurements at 96 weeks and Change from Baseline Immunological measurements at 96 weeks. Status: unknown.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04463784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04463784.